S&P 500   2,740.77 (-99.65%)
DOW   23,427.82 (+3.30%)
QQQ   201.11 (+2.36%)
AAPL   267.30 (+1.84%)
FB   172.39 (+4.13%)
MSFT   168.64 (+2.04%)
GOOGL   1,214.86 (+2.76%)
AMZN   2,016.49 (+0.95%)
CGC   15.06 (+5.02%)
NVDA   276.71 (+3.10%)
BABA   198.73 (+1.16%)
MU   48.05 (+3.62%)
GE   7.60 (+5.12%)
TSLA   536.00 (+3.83%)
AMD   49.19 (+3.51%)
T   30.70 (+4.25%)
ACB   0.82 (-1.20%)
F   4.77 (+5.30%)
NFLX   380.77 (+0.21%)
BAC   22.71 (+6.37%)
GILD   75.96 (-2.28%)
DIS   103.32 (+3.76%)
PRI   89.25 (+7.72%)
S&P 500   2,740.77 (-99.65%)
DOW   23,427.82 (+3.30%)
QQQ   201.11 (+2.36%)
AAPL   267.30 (+1.84%)
FB   172.39 (+4.13%)
MSFT   168.64 (+2.04%)
GOOGL   1,214.86 (+2.76%)
AMZN   2,016.49 (+0.95%)
CGC   15.06 (+5.02%)
NVDA   276.71 (+3.10%)
BABA   198.73 (+1.16%)
MU   48.05 (+3.62%)
GE   7.60 (+5.12%)
TSLA   536.00 (+3.83%)
AMD   49.19 (+3.51%)
T   30.70 (+4.25%)
ACB   0.82 (-1.20%)
F   4.77 (+5.30%)
NFLX   380.77 (+0.21%)
BAC   22.71 (+6.37%)
GILD   75.96 (-2.28%)
DIS   103.32 (+3.76%)
PRI   89.25 (+7.72%)
S&P 500   2,740.77 (-99.65%)
DOW   23,427.82 (+3.30%)
QQQ   201.11 (+2.36%)
AAPL   267.30 (+1.84%)
FB   172.39 (+4.13%)
MSFT   168.64 (+2.04%)
GOOGL   1,214.86 (+2.76%)
AMZN   2,016.49 (+0.95%)
CGC   15.06 (+5.02%)
NVDA   276.71 (+3.10%)
BABA   198.73 (+1.16%)
MU   48.05 (+3.62%)
GE   7.60 (+5.12%)
TSLA   536.00 (+3.83%)
AMD   49.19 (+3.51%)
T   30.70 (+4.25%)
ACB   0.82 (-1.20%)
F   4.77 (+5.30%)
NFLX   380.77 (+0.21%)
BAC   22.71 (+6.37%)
GILD   75.96 (-2.28%)
DIS   103.32 (+3.76%)
PRI   89.25 (+7.72%)
S&P 500   2,740.77 (-99.65%)
DOW   23,427.82 (+3.30%)
QQQ   201.11 (+2.36%)
AAPL   267.30 (+1.84%)
FB   172.39 (+4.13%)
MSFT   168.64 (+2.04%)
GOOGL   1,214.86 (+2.76%)
AMZN   2,016.49 (+0.95%)
CGC   15.06 (+5.02%)
NVDA   276.71 (+3.10%)
BABA   198.73 (+1.16%)
MU   48.05 (+3.62%)
GE   7.60 (+5.12%)
TSLA   536.00 (+3.83%)
AMD   49.19 (+3.51%)
T   30.70 (+4.25%)
ACB   0.82 (-1.20%)
F   4.77 (+5.30%)
NFLX   380.77 (+0.21%)
BAC   22.71 (+6.37%)
GILD   75.96 (-2.28%)
DIS   103.32 (+3.76%)
PRI   89.25 (+7.72%)
Log in

NYSE:GSKGlaxoSmithKline Stock Price, Forecast & News

$38.32
+0.41 (+1.08 %)
(As of 04/7/2020 09:42 AM ET)
Add
Compare
Today's Range
$38.18
Now: $38.32
$38.40
50-Day Range
$31.85
MA: $39.18
$43.74
52-Week Range
$31.43
Now: $38.32
$48.25
Volume158,832 shs
Average Volume6.96 million shs
Market Capitalization$95.62 billion
P/E Ratio16.10
Dividend Yield6.37%
Beta0.7
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More
GlaxoSmithKline logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.0Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 billion
Cash Flow$4.47 per share
Book Value$9.40 per share

Profitability

Net Income$5.93 billion

Miscellaneous

Employees95,490
Outstanding Shares2,495,280,000
Market Cap$95.62 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

How has GlaxoSmithKline's stock been impacted by COVID-19 (Coronavirus)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have decreased by 3.9% and is now trading at $38.32. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GlaxoSmithKline?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GlaxoSmithKline.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for GlaxoSmithKline.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, February, 5th. The pharmaceutical company reported $0.64 EPS for the quarter, missing analysts' consensus estimates of $0.68 by $0.04. The pharmaceutical company earned $11.46 billion during the quarter, compared to analyst estimates of $11.77 billion. GlaxoSmithKline had a return on equity of 57.93% and a net margin of 13.72%. View GlaxoSmithKline's earnings history.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, February 6th. Investors of record on Friday, February 21st will be paid a dividend of $0.5994 per share on Thursday, April 9th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 6.26%. The ex-dividend date of this dividend is Thursday, February 20th. This is an increase from GlaxoSmithKline's previous quarterly dividend of $0.50. View GlaxoSmithKline's dividend history.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $1.19-1.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.20.

What price target have analysts set for GSK?

11 brokerages have issued 1-year price targets for GlaxoSmithKline's shares. Their forecasts range from $45.00 to $45.00. On average, they expect GlaxoSmithKline's stock price to reach $45.00 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutGlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Johnson & Johnson (JNJ), Bank of America (BAC), Intel (INTC), Walt Disney (DIS) and General Electric (GE).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Chemung Canal Trust Co. (0.01%), Fulton Bank N.A. (0.00%), Blackhawk Capital Partners LLC. (0.00%), Cullinan Associates Inc. (0.00%), Global Trust Asset Management LLC (0.00%) and Gradient Investments LLC (0.00%). View institutional ownership trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Chemung Canal Trust Co., Fulton Bank N.A., Blackhawk Capital Partners LLC., and Global Trust Asset Management LLC. View insider buying and selling activity for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Gradient Investments LLC. View insider buying and selling activity for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $38.32.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $95.62 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe. View additional information about GlaxoSmithKline.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com/.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel